| __timestamp | Amicus Therapeutics, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 504755000 |
| Thursday, January 1, 2015 | 47269000 | 838526000 |
| Friday, January 1, 2016 | 71151000 | 1177697000 |
| Sunday, January 1, 2017 | 88671000 | 1320433000 |
| Monday, January 1, 2018 | 127200000 | 1556200000 |
| Tuesday, January 1, 2019 | 169861000 | 1834800000 |
| Wednesday, January 1, 2020 | 156407000 | 1346000000 |
| Friday, January 1, 2021 | 192710000 | 1824900000 |
| Saturday, January 1, 2022 | 213041000 | 2115900000 |
| Sunday, January 1, 2023 | 275270000 | 2631300000 |
| Monday, January 1, 2024 | 2954400000 |
In pursuit of knowledge
In the competitive landscape of biotechnology, understanding the financial strategies of industry leaders is crucial. Over the past decade, Regeneron Pharmaceuticals, Inc. and Amicus Therapeutics, Inc. have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Regeneron's SG&A expenses surged by over 420%, peaking at approximately $2.63 billion in 2023. In contrast, Amicus Therapeutics saw a more modest increase of around 1,230%, reaching $275 million in the same year. This disparity highlights Regeneron's aggressive expansion and market penetration strategies compared to Amicus's more conservative approach. The data underscores the importance of strategic financial management in sustaining growth and competitiveness in the biotech sector. As these companies continue to evolve, their SG&A trends offer valuable insights into their operational priorities and market positioning.
Pfizer Inc. or Regeneron Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and Amicus Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc. or Viatris Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Exelixis, Inc.
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs MorphoSys AG Trends and Insights
Regeneron Pharmaceuticals, Inc. or Ligand Pharmaceuticals Incorporated: Who Manages SG&A Costs Better?
Regeneron Pharmaceuticals, Inc. and Galapagos NV: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Novavax, Inc.
Comparing SG&A Expenses: Viatris Inc. vs Amicus Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Amicus Therapeutics, Inc. vs Catalyst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Amicus Therapeutics, Inc. and Novavax, Inc.